Research shows Ampion mimics anti-inflammatory effects of steroids but without adverse effects
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced findings of pre-clinical research demonstrating Ampio's lead drug candidate, Ampion, provides some of the same anti-inflammatory... Read More
Tuesday April 20, 2021 0 comments
Ampio study: Ampion inhibits key inflammatory pathway in COVID-19 and lupus nephritis
ENGLEWOOD -- Ampio Pharmaceuticals (NYSE American: AMPE) announced results of a pre-clinical study demonstrating Ampion inhibits an important pro-inflammatory pathway in the types of immune cells... Read More
Friday April 9, 2021 0 comments
Ampio initiates pivotal Ampion osteoarthritis trial
ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) announced it has begun a single injection study to meet the unmet medical need of treating the severe pain and loss of function... Read More
Monday May 1, 2017 0 comments
Ampio Pharmaceuticals launches clinical trial of Ampion for treatment of osteoarthritis of the hand
ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced patient dosing has begun in the initial clinical trial of Ampion for the treatment of pain due to osteoarthritis of the... Read More
Tuesday May 10, 2016 0 comments
Ampio advances cancer drug into preclinical development after patents granted in U.S., Canada, Europe and China
GREENWOOD VILLAGE - Ampio Pharmaceuticals Inc. (Nasdaq: AMPE) announced the advancement of NCE001 to preclinical development for the treatment of gliobastoma multiforme, renal cell carcinoma and... Read More
Tuesday July 17, 2012 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
